Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex GI Safety, Warfarin Claims Over Vioxx Need Corrective Letter - FDA

Executive Summary

Pharmacia should issue a Celebrex "Dear Healthcare Provider Letter" to correct violative safety information disseminated about the COX-2 inhibitor during an audioconference series and in two professional sales pieces, a Feb. 1 FDA warning letter states.

You may also be interested in...



Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test

The Vioxx withdrawal will prompt renewed debate over DTC advertising

Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test

The Vioxx withdrawal will prompt renewed debate over DTC advertising

Merck Vioxx Warning Letter Could Be Incentive For Large Cardio Safety Study

Merck's Vioxx warning letter may serve as an additional incentive for the company to conduct a large cardiovascular safety study.

Related Content

UsernamePublicRestriction

Register

PS037323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel